2 Healthcare Stocks That Could Soar Over the Next 5 Years

Moderna is up ~73% YTD as its personalized cancer vaccine mRNA‑4157 showed a significant reduction in recurrence/death vs. Keytruda alone in a five‑year Phase 2 follow‑up, and the company is advancing a flu vaccine and multiple oncology programs. Abivax’s obefazimod met the Phase 3 primary endpoint for clinical remission in moderate‑to‑severe ulcerative colitis (with ~47.3% of patients previously treated unsuccessfully) and maintenance data due in Q2 could be a material catalyst. Both stocks offer substantial upside for risk‑tolerant investors but carry above‑average binary risk from clinical and regulatory setbacks, and Abivax has no approved products, increasing downside vulnerability.

Analysis

Platform biotechs with scalable RNA or small-molecule franchises create a predictable set of second-order winners: LNP and lipid suppliers, specialty CDMOs, and cloud/accelerated compute providers that service sequence-to-design workflows. Concentration in a handful of upstream suppliers creates a brittle supply chain — a single fill/finish hiccup or LNP shortage could delay multiple launches simultaneously and reprice risk premia across the sector within 3–9 months.

Commercial success will be decided post-approval by two non-clinical levers: formulary placement/reimbursement negotiation and margin on in-house vs outsourced manufacturing. These play out over years, not quarters; a favorable readout can pop equity prices in days, but durable revenues require contracting with payers and scale certification of manufacturing lines, typically a 12–36 month runway.

Near-term macro catalysts are clinical readouts and CMC scale milestones; tail risks are safety signals, CRLs, or payer-imposed price controls that can wipe out expected NPV multiples quickly. Given binary outcome risk, option-structured exposures and small-size equity stakes are superior to outright long positions — they cap downside while keeping upside convexity for acquisition or label-expansion scenarios.

The market consensus underweights the compute/AI demand tied to platform iteration velocity; owners of on-prem GPU capacity and foundries for novel delivery chemistries may see outsized revenue growth even if headline approvals disappoint. That implies a cross-asset trade: patient, convex exposure to the biotech binary plus a hedge into technology names that monetize faster, reducing portfolio carrying cost of the clinical binary.

Key Decisions for Investors

• MRNA — Buy a 12–18 month call spread (debit) sized to 0.30% NAV (buy long-dated calls, sell higher strike to finance) to capture clinical/commercial milestones; target 2x–4x return on positive readouts, max loss = premium. Exit/trim on a 50% gain or on adverse safety/regulatory signal.
• ABVX — Tactical asymmetric bet: purchase 24-month OTM calls sized to 0.10% NAV plus a small 0.10% NAV outright equity stake for deal optionality. Rationale: acquisition or approval can produce 3x–10x outcomes; downside is binary (near-total loss) so size accordingly and treat as high-convexity lottery ticket.
• NVDA / INTC — Buy NVDA 6–12 month calls or accumulate INTC stock sized to 0.50% NAV to capture secular compute demand from AI-driven drug design and trial simulation. Expect >30% upside if compute spend accelerates; use INTC as cheaper, lower-vol hedge if NVDA premiums are rich.
• IBB/XBI hedge — Purchase 3–6 month put spreads on a biotech ETF sized to 0.15% NAV to protect against correlated drawdowns from clinical or regulatory shocks around major sector readouts. Structure to cap cost while offsetting >60% of an idiosyncratic single-stock collapse.